Yushin Company (6482) investor relations material

Executive summary

• FY2026 net sales declined 11.6% year-over-year to 23,101 million yen, mainly due to a sharp drop in custom-ordered medical equipment sales, despite growth in robot and palletizing robot sales in Asia and Japan.

• Operating profit fell 68.0% year-over-year to 826 million yen, impacted by lower sales, higher raw material and labor costs, and increased R&D spending for future growth.

• Profit attributable to owners of parent decreased 83.1% year-over-year to 286 million yen, affected by impairment losses and lower extraordinary gains.

• FY2027 forecasts anticipate an 8.2% increase in net sales to 25,000 million yen and a 57.3% rise in operating profit to 1,300 million yen, driven by recovering demand for custom-ordered medical equipment and continued automation needs.

• Focus on expanding global sales, especially in Europe, and strengthening product competitiveness and maintenance services.

Financial highlights

• FY2026 gross profit decreased 15.9% year-over-year to 9,051 million yen; gross margin dropped from 41.2% to 39.2%.

• Ordinary profit declined 64.2% to 908 million yen; profit attributable to owners of parent fell 83.1% to 286 million yen.

• Basic earnings per share dropped to 8.51 yen from 49.74 yen year-over-year.

• FY2027 forecasts: gross profit up 6.1% to 9,600 million yen, ordinary profit up 43.1% to 1,300 million yen, and profit attributable to owners of parent up 213.8% to 900 million yen.

• Equity ratio remained high at 86.3% (up from 85.5% the previous year).

Outlook and guidance

• FY2027 expects increased sales from AI-related demand, custom-ordered medical equipment, and palletizing robots, though market uncertainty remains due to geopolitical risks.

• Operating profit growth expected from higher sales and cost/productivity initiatives, despite ongoing cost pressures.

• Continued investment in human resources and R&D to drive medium- to long-term growth.